Citius Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	2018 - 2013
Net Income	-36.2	-33.69	-33.64	-24.51	-17.55	-15.56	Upgrade
Depreciation & Amortization	0.2	0.19	0.18	0.16	0.15	0	Upgrade
Share-Based Compensation	10.56	6.72	4.28	1.52	1.33	0.93	Upgrade
Other Operating Activities	-4.87	-3.43	0.82	-2.88	-0.87	2.2	Upgrade
Operating Cash Flow	-30.3	-29.06	-28.36	-24.25	-16.93	-12.44	Upgrade
Capital Expenditures	0	0	0	-0.01	-0	0	Upgrade
Other Investing Activities	-	-	-	-40	-	-	Upgrade
Investing Cash Flow	0	0	0	-40.01	-0	0	Upgrade
Share Issuance / Repurchase	13.8	13.83	0	120.64	22.73	11.15	Upgrade
Debt Issued / Paid	0	0	0	-0.17	0.16	0	Upgrade
Other Financing Activities	-	-	-	0	-	-	Upgrade
Financing Cash Flow	13.8	13.83	0	120.47	22.9	11.15	Upgrade
Net Cash Flow	-16.51	-15.23	-28.36	56.21	5.97	-1.29	Upgrade
Free Cash Flow	-30.3	-29.06	-28.36	-24.26	-16.93	-12.44	Upgrade
Free Cash Flow Per Share	-0.19	-0.19	-0.19	-0.22	-0.43	-0.62	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).